- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03311295
MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States (MAVERIC US)
April 26, 2021 updated by: Mvrx, Inc.
The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Candidates must meet ALL of the following criteria to be enrolled in the study.
- Is ambulatory, able and willing to comply with the study protocol and has provided written informed consent
- Age 21-85, inclusive
- Trans-septal catheterization is determined to be feasible by the treating physician
- NYHA class II-IV heart failure of any etiology
- Symptomatic with MR grade ≥ 2+
- LVEF < 40%
- LVEDD > 50 mm and ≤ 75 mm
- No anticipated change in patient's cardiac medication regimen anticipated throughout the course of the study.
- In the opinion of the investigator and heart surgery team, the patient is not an appropriate candidate for surgery, and the use of the ARTO System is technically feasible
Exclusion Criteria:
Candidates will be excluded from enrollment in the study if ANY of the following conditions apply.
- In the opinion of the Investigator, the femoral vein and internal jugular vein cannot accommodate a 16 F catheter or the presence of an inferior vena cava (IVC) filter would interfere with advancement of the catheter or ipsilateral DVT is present
- Significant structural abnormality of the mitral valve (e.g., flail, prolapse, leaflet calcification)
- Significant mitral annular calcification
- Hemodynamic instability (systolic pressure < 90 mmHg without afterload reduction or cardiogenic shock or the need for inotropic support or intra-aortic balloon pump)
- Prior mitral valve surgery or valvuloplasty or any currently implanted prosthetic valve or VAD
- History of, or active, rheumatic heart disease
- History of Atrial Septal Defects (ASD), whether repaired or not
- History of previously repaired PFO or PFO associated with clinical symptoms (e.g., cerebral ischemia) within 6 months of the planned investigational procedure
- In the opinion of the investigator, an atrial septal aneurysm is present that may interfere with transseptal crossing
- Serum creatinine > 2.5 mg/dL or dialysis dependent
- No access to coronary sinus and/or great cardiac vein
- Platelet count < 100 x 103 cells/mm3
- Evidence of active infection (fever with temperature > 38°C and/or WBC > 15,000) or endocarditis
- Echocardiographic evidence of mass intracardiac thrombus
- Patients on prescribed dual antiplatelet therapy (asprin + any P2Y12 inhibitor) that cannot be discontinued.
- Percutaneous coronary intervention or surgery anticipated within the 6 month follow up period following the investigational procedure
- Biventricular pacing initiated or anticipated within 6 months of the planned investigational procedure
- Evidence of an acute myocardial infarction within 12 weeks of the planned investigational procedure
- Stroke or TIA within 6 months of the planned investigational procedure
- GI bleeding within 6 months of the planned investigational procedure
- Intravenous drug abuse or suspected inability to adhere to follow-up
- Patients in whom TTE, TEE or ICE is contraindicated
- Contraindication to CT scan
- A known hypersensitivity or contraindication to study or procedure medications (specifically aspirin, clopidogrel and heparin) that cannot be adequately managed medically
- A known allergy or hypersensitivity to nickel
- A known need for any other cardiac surgery including surgery for coronary artery disease, atrial fibrillation, pulmonic, aortic or tricuspid valve disease
- In the judgment of the Investigator, patients in whom the presence of a permanent pacemaker or pacing leads would interfere with placement of the test device or the placement of the test device would disrupt the leads
- Irreversible bleeding disorder, history of bleeding diathesis or coagulopathy or refuses blood transfusion
- Evidence of disease or condition expected to compromise survival (< 1 year) or ability to complete follow-up assessments
- Pregnant or breastfeeding women
- Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials]
- Patient not a candidate for emergent surgical bailout in case of need
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARTO System
|
The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Major Adverse Event Rate to 30 Days post-procedure
Time Frame: 30 days post procedure
|
Major Adverse Events (MAEs) will be categorized and defined in accordance with the relation to the procedure and device.
|
30 days post procedure
|
Efficacy: Mitral regurgitation grade by ASE criteria and change from baseline to 1 year
Time Frame: Baseline to 1 year
|
Mitral regurgitation grade by ASE criteria and change from baseline to 1 year evaluated by 2-D transthoracic echocardiogram
|
Baseline to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Reginald Low, MD, University California Davis
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 3, 2018
Primary Completion (ACTUAL)
April 26, 2021
Study Completion (ACTUAL)
April 26, 2021
Study Registration Dates
First Submitted
October 11, 2017
First Submitted That Met QC Criteria
October 11, 2017
First Posted (ACTUAL)
October 17, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 28, 2021
Last Update Submitted That Met QC Criteria
April 26, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- US042616
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Insufficiency
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Abbott Medical DevicesRecruitingCardiovascular Diseases | Heart Valve Diseases | Mitral Regurgitation | Mitral Valve Insufficiency | Valve Disease, Heart | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
4C Medical Technologies, Inc.RecruitingMitral Regurgitation | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Mitral IncompetenceUnited States
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Mitral Repair | Mitral Valve | Annuloplasty | Edwards CardiobandSwitzerland, Germany, Italy
-
Assistance Publique - Hôpitaux de ParisEuropean Association of Cardiovascular ImagingNot yet recruitingAortic Valve Stenosis | Aortic Valve Disease | Heart Valve Diseases | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Tricuspid Valve Insufficiency | Mitral Valve Disease | Tricuspid Valve Disease | Mitral Valve Insufficiency and... and other conditionsFrance
Clinical Trials on ARTO System
-
Mvrx, Inc.Active, not recruitingMitral Valve RegurgitationLatvia, Australia, United Kingdom, France, Italy
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting